Amylin pharmaceuticals reports first quarter 2012 financial results
Amylin Pharmaceuticals, 04/27/2012
While still early, we have seen a positive uptake of BYDUREON in the U.S. and Europe, and are pleased with the execution of our U.S. commercial launch," said Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals. "We have also made important progress against our other corporate priorities during the quarter. The recently expanded use of BYETTA with insulin glargine in the U.S. and Europe enables patients to achieve better glycemic control, without weight gain or an increased risk of hypoglycemia.